REM behavior disorder (RBD) is one of the most important sleep disorders for longevity psychiatry. Patients with RBD lose the normal REM-sleep muscle atonia and enact their dreams — kicking, punching, vocalizing, sometimes injuring themselves or bed partners. The disorder is itself sleep-disrupting and dangerous, but the longevity-psychiatry significance is broader: idiopathic RBD is now recognized as a prodromal phenotype for alpha-synuclein pathology, with a substantial proportion of patients progressing to Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy over 10–25 years of follow-up. Recognition matters not just for treating the immediate sleep disorder but for opening the conversation about cognitive trajectory.
The clinical recognition. Patients with RBD enact dreams — typically violent or action-content dreams — with motor and vocal behavior during sleep. Bed partners report kicking, punching, jumping, falling out of bed, yelling, sometimes injuring the partner. The patient often awakens with the dream content and is aware of the behavior. Episodes typically occur in the second half of the night when REM sleep predominates. Onset is most common in adults over 50, with male predominance. The presentation can be mild (occasional movements) or severe (regular dangerous behavior); both are clinically meaningful.
The diagnosis requires polysomnography. Sleep study with EMG monitoring confirms loss of REM-sleep atonia (REM sleep without atonia, RSWA) and documents the behavior. The differential includes obstructive sleep apnea (apnea-related arousals can mimic RBD), nocturnal seizures, parasomnias of NREM sleep (sleepwalking, night terrors), and PTSD-related nightmares. The PSG distinguishes these and confirms RBD diagnosis; clinical history alone is suggestive but not definitive.
The synucleinopathy connection is now well-established. Patients with idiopathic RBD show substantially elevated conversion to Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy in long-follow-up cohorts. Conversion rates reach 50–80% over 10–15 years in some series; the mechanism is that the brainstem nuclei responsible for REM atonia (sublaterodorsal nucleus, magnocellular reticular formation) are early targets of alpha-synuclein pathology, and the RBD presentation reflects the same disease process that will later affect midbrain dopamine systems and cortical regions. The clinical implication is substantial — RBD is one of the most specific prodromal markers of synucleinopathy currently identifiable.
Treatment addresses immediate safety and considers the prodromal context. Bed safety modifications — padded bed rails, removing nearby objects, partner sleeping in another bed if injury risk is high — are first-line and frequently effective for mild cases. Melatonin (3–12mg qhs) has moderate evidence and a favorable safety profile; it is often the first pharmacological choice. Clonazepam (0.5–2mg qhs) has long-standing evidence in RBD but carries the chronic-benzodiazepine cognitive concerns that are particularly relevant in this population. The discipline is to use the lowest-cost intervention that produces adequate safety and to weigh the cognitive cost of benzodiazepines against the safety needs.
The longitudinal conversation matters. When idiopathic RBD is diagnosed, the patient deserves the conversation about the prodromal significance — what is known about conversion risk, what monitoring is appropriate, what early intervention strategies are available. The cognitive-protection prescription (Stages 9–28 collectively) takes on additional significance in this population; the Modifiable Twelve factors may bend the trajectory. Regular cognitive and motor evaluation (every 6–12 months) allows early recognition of converting illness. Some patients prefer detailed information; others prefer a less detailed framing; the conversation should match the patient's preferences while ensuring they have the information needed for informed decisions about lifestyle and monitoring. The recognition of RBD is one of the most important clinical moments in longevity psychiatry — it identifies a patient who can engage in the most powerful prevention strategies available with the most relevant biological context.